Advances in the therapeutic use of mammalian target of rapamycin (mTOR) inhibitors in dermatology

Journal of the American Academy of Dermatology

Volumn 72, Issue 5, 2015, Pages 879-889

  Fogel, Alexander L ^a   Hill, Sharleen ^b   Teng, Joyce M C ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Cambridge Mansions   (United Kingdom)

Author keywords

antiproliferative; autoimmune; drug repurposing; genodermatosis; immunosuppression; inflammatory; mammalian target of rapamycin; neoplasia; percutaneous therapy; rapamycin; sirolimus; vascular anomalies

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; VASCULOTROPIN; IMMUNOSUPPRESSIVE AGENT; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ARTICLE; BIRT HOGG DUBE SYNDROME; CAPILLARY HEMANGIOMA; CLINICAL TRIAL (TOPIC); COMPLEX VASCULAR NEOPLASM; CONGENITAL BLOOD VESSEL MALFORMATION; CONGENITAL PACHYONYCHIA; CREATININE BLOOD LEVEL; CUTANEOUS T CELL LYMPHOMA; DERMATOLOGY; DRUG ERUPTION; GENODERMATOSIS; HAMARTOMA; HEREDITARY FIBROMA; HEREDITARY KERATINOPATHY; HUMAN; KAPOSI SARCOMA; LONG TERM CARE; MALIGNANT NEOPLASTIC DISEASE; MUCOSA INFLAMMATION; NAIL COLOR DEFECT; NAIL DISEASE; NAIL FRAGILITY; NEVUS FLAMMEUS; NON MELANOMA SKIN CANCER; NONHUMAN; ONYCHOLYSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PRURITUS; PTEN HAMARTOMA TUMOR SYNDROME; RANDOMIZED CONTROLLED TRIAL (TOPIC); STOMATITIS; SYSTEMIC SCLEROSIS; TUBEROUS SCLEROSIS COMPLEX; VASCULAR TUMOR; XEROSIS; ANTAGONISTS AND INHIBITORS; SKIN DISEASES; SKIN NEOPLASMS; TUBEROUS SCLEROSIS;

HUMANS; IMMUNOSUPPRESSIVE AGENTS; SKIN DISEASES; SKIN NEOPLASMS; TOR SERINE-THREONINE KINASES; TUBEROUS SCLEROSIS;

EID: 84928268474     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2015.01.014     Document Type: Review

References (78)

1. K.V. Paghdal, and R.A. Schwartz Sirolimus (rapamycin): from the soil of Easter Island to a bright future J Am Acad Dermatol 57 2007 1046 1050
2. L.M. Ballou, and R.Z. Lin Rapamycin and mTOR kinase inhibitors J Chem Biol 1 2008 27 36
3. Pfizer. Rapamune package insert. Online2012. Available at: http://labeling.pfizer.com/showlabeling.aspx?id=139. Accessed August 1, 2014.
4. R.P. Hickerson, D. Leake, L.N. Pho, S.A. Leachman, and R.L. Kaspar Rapamycin selectively inhibits expression of an inducible keratin (K6a) in human keratinocytes and improves symptoms in pachyonychia congenita patients J Dermatol Sci 56 2009 82 88
5. R.S. Foster, L.J. Bint, and A.R. Halbert Topical 0.1% rapamycin for angiofibromas in pediatric patients with tuberous sclerosis: a pilot study of four patients Australas J Dermatol 53 2012 52 56
6. W. Jia, V. Sun, and N. Tran et al. Long-term blood vessel removal with combined laser and topical rapamycin antiangiogenic therapy: implications for effective port wine stain treatment Lasers Surg Med 42 2010 105 112
7. A.D. Ormerod, S.A. Shah, P. Copeland, G. Omar, and A. Winfield Treatment of psoriasis with topical sirolimus: preclinical development and a randomized, double-blind trial Br J Dermatol 152 2005 758 764
8. J. Jozwiak, S. Jozwiak, and M. Oldak Molecular activity of sirolimus and its possible application in tuberous sclerosis treatment Med Res Rev 26 2006 160 180
9. D. Benjamin, M. Colombi, C. Moroni, and M.N. Hall Rapamycin passes the torch: a new generation of mTOR inhibitors Nat Rev Drug Discov 10 2011 868 880
10. Drugs@FDA: FDA-approved drug products. Online: U.S. Food and Drug Administration; 2014. Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm. Accessed August 1, 2014.
11. L. Peuvrel, G. Quereux, A. Brocard, M. Saint-Jean, and B. Dreno Onychopathy induced by temsirolimus, a mammalian target of rapamycin inhibitor Dermatology 224 2012 204 208
12. M. Gandhi, T. Kuzel, and M. Lacouture Eosinophilic rash secondary to temsirolimus Clin Genitourin Cancer 7 2009 E34 E36
13. D.N. Franz, J. Leonard, and C. Tudor et al. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex Ann Neurol 59 2006 490 498
14. D.N. Franz Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis Expert Rev Anticancer Ther 11 2011 1181 1192
15. D. Tiberio, D.N. Franz, and J.R. Phillips Regression of a cardiac rhabdomyoma in a patient receiving everolimus Pediatrics 127 2011 e1335 e1337
16. D.M. Davies, P.J. de Vries, and S.R. Johnson et al. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial Clin Cancer Res 17 2011 4071 4081
17. A. Casanova, R. Maria Giron, O. Acosta, M. Barron, C. Valenzuela, and J. Ancochea Lymphangioleiomyomatosis treatment with sirolimus Archivos de bronconeumologia 47 2011 470 472
18. M.N. Luijten, S.G. Basten, and T. Claessens et al. Birt-Hogg-Dube syndrome is a novel ciliopathy Hum Mol Genet 22 2013 4383 4397
19. Steense Mv. Topical rapamycin for fibrofolliculomas. In: U. N. I. o. Health editor. Online2013. Available at: http://clinicaltrials.gov/ct2/show/NCT00928798?term=birt+hogg+dube&rank=2. Accessed August 1, 2014.
20. T.M. Starink, A.C. Houweling, and M.B. van Doorn et al. Familial multiple discoid fibromas: a look-alike of Birt-Hogg-Dube syndrome not linked to the FLCN locus J Am Acad Dermatol 66 2012 259.e1 259.e9
21. R. Pilarski, and C. Eng Will the real Cowden syndrome please stand up (again)? Expanding mutational and clinical spectra of the PTEN hamartoma tumour syndrome J Med Genet 41 2004 323 326
22. C.H. Squarize, R.M. Castilho, and J.S. Gutkind Chemoprevention and treatment of experimental Cowden's disease by mTOR inhibition with rapamycin Cancer Res 68 2008 7066 7072
23. D.J. Marsh, T.N. Trahair, and J.L. Martin et al. Rapamycin treatment for a child with germline PTEN mutation Nat Clin Pract Oncol 5 2008 357 361
24. Rajan A. Sirolimus to treat Cowden syndrome and other PTEN hamartomatous tumor syndromes. In: T. U. S. N. I. o. Health editor. ClinicalTrials.gov2009. Available at: http://www.clinicaltrials.gov/ct2/show/results/NCT00971789?term=pten+rapamycin&rank=1§=X736015#outcome2. Accessed August 1, 2014.
25. J.C. Chamcheu, I.A. Siddiqui, D.N. Syed, V.M. Adhami, M. Liovic, and H. Mukhtar Keratin gene mutations in disorders of human skin and its appendages Arch Biochem Biophys 508 2011 123 137
26. A. Peramo, and C.L. Marcelo Visible effects of rapamycin (sirolimus) on human skin explants in vitro Arch Dermatol Res 305 2013 163 171
27. ClinicalTrials.gov. Online: The United States National Institutes of Health; 2014.
28. M. Guba, P. von Breitenbuch, and M. Steinbauer et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor Nat Med 8 2002 128 135
29. Y.S. Kwon, H.S. Hong, J.C. Kim, J.S. Shin, and Y. Son Inhibitory effect of rapamycin on corneal neovascularization in vitro and in vivo Invest Ophthalmol Visl Sci 46 2005 454 460
30. B. Perry, J. Banyard, and E.R. McLaughlin et al. AKT1 overexpression in endothelial cells leads to the development of cutaneous vascular malformations in vivo Arch Dermatol 143 2007 504 506
31. T.L. Phung, D.A. Oble, W. Jia, L.E. Benjamin, M.C. Mihm Jr., and J.S. Nelson Can the wound healing response of human skin be modulated after laser treatment and the effects of exposure extended? Implications on the combined use of the pulsed dye laser and a topical angiogenesis inhibitor for treatment of port wine stain birthmarks Lasers Surg Med 40 2008 1 5
32. M.D. Shirley, H. Tang, and C.J. Gallione et al. Sturge-Weber syndrome and port-wine stains caused by somatic mutation in GNAQ N Engl J Med 368 2013 1971 1979
33. F. Shirazi, C. Cohen, L. Fried, and J.L. Arbiser Mammalian target of rapamycin (mTOR) is activated in cutaneous vascular malformations in vivo Lymph Res Biol 5 2007 233 236
34. J.S. Nelson, T.E. Milner, B. Anvari, B.S. Tanenbaum, L.O. Svaasand, and S. Kimel Dynamic epidermal cooling in conjunction with laser-induced photothermolysis of port wine stain blood vessels Lasers Surg Med 19 1996 224 229
35. W. Tan, W. Jia, V. Sun, M.C. Mihm Jr., and J.S. Nelson Topical rapamycin suppresses the angiogenesis pathways induced by pulsed dye laser: molecular mechanisms of inhibition of regeneration and revascularization of photocoagulated cutaneous blood vessels Lasers Surg Med 44 2012 796 804
36. R. Loewe, D.A. Oble, T. Valero, L. Zukerberg, M.C. Mihm Jr., and J.S. Nelson Stem cell marker upregulation in normal cutaneous vessels following pulsed-dye laser exposure and its abrogation by concurrent rapamycin administration: implications for treatment of port-wine stain birthmarks J Cutan Pathol 37 Suppl 1 2010 76 82
37. D. Metry, I.J. Frieden, and C. Hess et al. Propranolol use in PHACE syndrome with cervical and intracranial arterial anomalies: collective experience in 32 infants Pediatr Dermatol 30 2013 71 89
38. S. Kaylani, A.J. Theos, and J.G. Pressey Treatment of infantile hemangiomas with sirolimus in a patient with PHACE syndrome Pediatr Dermatol 30 2013 e194 e197
39. J. Blatt, J. Stavas, B. Moats-Staats, J. Woosley, and D.S. Morrell Treatment of childhood kaposiform hemangioendothelioma with sirolimus Pediatr Blood Cancer 55 2010 1396 1398
40. Y. Nobuhara, N. Onoda, and K. Fukai et al. TIE2 gain-of-function mutation in a patient with pancreatic lymphangioma associated with blue rubber-bleb nevus syndrome: report of a case Surg today 36 2006 283 286
41. H. Yuksekkaya, O. Ozbek, M. Keser, and H. Toy Blue rubber bleb nevus syndrome: successful treatment with sirolimus Pediatrics 129 2012 e1080 e1084
42. A.M. Hammill, M. Wentzel, and A. Gupta et al. Sirolimus for the treatment of complicated vascular anomalies in children Pediatr Blood Cancer 57 2011 1018 1024
43. T.D. Carr, J. DiGiovanni, C.J. Lynch, and L.M. Shantz Inhibition of mTOR suppresses UVB-induced keratinocyte proliferation and survival Cancer Prev Res 5 2012 1394 1404
44. L.A. Checkley, O. Rho, T. Moore, S. Hursting, and J. DiGiovanni Rapamycin is a potent inhibitor of skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate Cancer Prev Res 4 2011 1011 1020
45. J.D. Hainsworth, J.R. Infante, and D.R. Spigel et al. Bevacizumab and everolimus in the treatment of patients with metastatic melanoma: a phase 2 trial of the Sarah Cannon Oncology Research Consortium Cancer 116 2010 4122 4129
46. M. Kremer, K. Sliva, C.D. Klemke, and B.S. Schnierle Cutaneous T-cell lymphoma cells are sensitive to rapamycin Exp Dermatol 19 2010 800 805
47. S. Yaich, K. Charfeddine, and S. Zaghdane et al. Sirolimus for the treatment of Kaposi sarcoma after renal transplantation: a series of 10 cases Transplant Proc 44 2012 2824 2826
48. J.M. Campistol, A. Gutierrez-Dalmau, and J.V. Torregrosa Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma Transplantation 77 2004 760 762
49. G. Stallone, A. Schena, and B. Infante et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients N Engl J Med 352 2005 1317 1323
50. D. Wolff, M. Schleuning, and S. von Harsdorf et al. Consensus Conference on Clinical Practice in Chronic GVHD: second-line treatment of chronic graft-versus-host disease Biol Blood Marrow Transplant 17 2011 1 17
51. J.T. Schnider, M. Weinstock, and J.A. Plock et al. Site-specific immunosuppression in vascularized composite allotransplantation: prospects and potential Clini Dev Immunol 2013 2013 495212
52. T.I. Su, D. Khanna, and D.E. Furst et al. Rapamycin versus methotrexate in early diffuse systemic sclerosis: results from a randomized, single-blind pilot study Arthritis Rheum 60 2009 3821 3830
53. Z. Jedlickova, I. Burlakova, G. Bug, H. Baurmann, R. Schwerdtfeger, and M. Schleuning Therapy of sclerodermatous chronic graft-versus-host disease with mammalian target of rapamycin inhibitors Biol Blood Marrow Transplant 17 2011 657 663
54. A. Soria, S. Agbo-Godeau, A. Taieb, and C. Frances Treatment of refractory oral erosive lichen planus with topical rapamycin: 7 cases Dermatology 218 2009 22 25
55. J.W. Wheless, and H. Almoazen A novel topical rapamycin cream for the treatment of facial angiofibromas in tuberous sclerosis complex J Child Neurol 28 2013 933 936
56. Oxford Centre for Evidence-based Medicine - Levels of Evidence. Online2009. Available at: http://www.cebm.net/?o=1025. Accessed August 1, 2014.
57. J.S. Wee, H. Chong, J. Natkunarajah, P.S. Mortimer, and Y. Moosa Familial multiple discoid fibromas: unique histological features and therapeutic response to topical rapamycin Br J Dermatol 169 2013 177 180
58. A.M. Poot, and M.F. Jonkman Topical sirolimus for oral pemphigus vulgaris: 3 unresponsive cases J Am Acad Dermatol 67 2012 e228 e229
59. A.K. Haemel, A.L. O'Brian, and J.M. Teng Topical rapamycin: a novel approach to facial angiofibromas in tuberous sclerosis Arch Dermatol 146 2010 715 718
60. C.M. DeKlotz, A.E. Ogram, S. Singh, S. Dronavalli, and J.L. MacGregor Dramatic improvement of facial angiofibromas in tuberous sclerosis with topical rapamycin: optimizing a treatment protocol Arch Dermatol 147 2011 1116 1117
61. M.M. Mutizwa, D.R. Berk, and M.J. Anadkat Treatment of facial angiofibromas with topical application of oral rapamycin solution (1mgmL(-1)) in two patients with tuberous sclerosis Br J Dermatol 165 2011 922 923
62. M. Wataya-Kaneda, M. Tanaka, A. Nakamura, S. Matsumoto, and I. Katayama A topical combination of rapamycin and tacrolimus for the treatment of angiofibroma due to tuberous sclerosis complex (TSC): a pilot study of nine Japanese patients with TSC of different disease severity Br J Dermatol 165 2011 912 916
63. E. Kaufman McNamara, A.R. Curtis, and A.B. Fleischer Jr. Successful treatment of angiofibromata of tuberous sclerosis complex with rapamycin J Dermatolog Treat 23 2012 46 48
64. M.K. Koenig, A.A. Hebert, and J. Roberson et al. Topical rapamycin therapy to alleviate the cutaneous manifestations of tuberous sclerosis complex: a double-blind, randomized, controlled trial to evaluate the safety and efficacy of topically applied rapamycin Drugs R D 12 2012 121 126
65. R. Salido, G. Garnacho-Saucedo, and I. Cuevas-Asencio et al. Sustained clinical effectiveness and favorable safety profile of topical sirolimus for tuberous sclerosis-associated facial angiofibroma J Eur Acad Dermatol Venereol 26 2012 1315 1318
66. T. Truchuelo, B. Diaz-Ley, L. Rios, J. Alcantara, and P. Jaen Facial angiofibromas treated with topical rapamycin: an excellent choice with fast response Dermatol Online J 18 2012 15
67. M. Wataya-Kaneda, M. Tanaka, A. Nakamura, S. Matsumoto, and I. Katayama A novel application of topical rapamycin formulation, an inhibitor of mTOR, for patients with hypomelanotic macules in tuberous sclerosis complex Arch Dermatol 148 2012 138 139
68. M. Tanaka, M. Wataya-Kaneda, A. Nakamura, S. Matsumoto, and I. Katayama First left-right comparative study of topical rapamycin vs vehicle for facial angiofibromas in patients with tuberous sclerosis complex Br J Dermatol 169 2013 1314 1318
69. J. Tu, R.S. Foster, L.J. Bint, and A.R. Halbert Topical rapamycin for angiofibromas in pediatric patients with tuberous sclerosis: follow up of a pilot study and promising future directions Australas J Dermatol 55 2014 63 69
70. S. Euvrard, E. Morelon, and L. Rostaing et al. Sirolimus and secondary skin-cancer prevention in kidney transplantation N Engl J Med 367 2012 329 339
71. S. Reitamo, P. Spuls, and B. Sassolas et al. Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial Br J Dermatol 145 2001 438 445
72. T.R. Hartman, E. Nicolas, and A. Klein-Szanto et al. The role of the Birt-Hogg-Dube protein in mTOR activation and renal tumorigenesis Oncogene 28 2009 1594 1604
73. E.A. Griffard, H.H. McCoppin, J. Wieberg, and M. Feldman The cutaneous effects of post-transplant immunosuppression with cyclosporine in Muir-Torre syndrome J Am Acad Dermatol 64 2011 e86 e87
74. T.S. Chen, M.E. Goldyne, E.F. Mathes, I.J. Frieden, and A.E. Gilliam Pediatric teledermatology: observations based on 429 consults J Am Acad Dermatol 62 2010 61 66
75. S. Riou, E. Morelon, L. Guibaud, F. Chotel, F. Dijoud, and P. Marec-Berard Efficacy of rapamycin for refractory hemangioendotheliomas in Maffucci's syndrome J Clin Oncol 30 2012 e213 e215
76. W. Baumer, B. Sulzle, and H. Weigt et al. Cilomilast, tacrolimus and rapamycin modulate dendritic cell function in the elicitation phase of allergic contact dermatitis Br J Dermatol 153 2005 136 144
77. S.A. Grando, V.T. Laquer, and H.M. Le Sirolimus for acute pemphigus vulgaris: a case report and discussion of dualistic action providing for both immunosuppression and keratinocyte protection J Am Acad Dermatol 65 2011 684 686
78. F. Syed, H.J. Sanganee, A. Bahl, and A. Bayat Potent dual inhibitors of TORC1 and TORC2 complexes (KU-0063794 and KU-0068650) demonstrate in vitro and ex vivo anti-keloid scar activity J Invest Dermatol 133 2013 1340 1350